↓ Skip to main content

Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]

Overview of attention for article published in BMC Ophthalmology, June 2006
Altmetric Badge

Mentioned by

facebook
2 Facebook pages

Citations

dimensions_citation
70 Dimensions

Readers on

mendeley
76 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]
Published in
BMC Ophthalmology, June 2006
DOI 10.1186/1471-2415-6-23
Pubmed ID
Authors

Hossein Bahrami, Michele Melia, Gislin Dagnelie

Abstract

There is no generally accepted medical or surgical treatment to stop the progressive course of retinitis pigmentosa. Previous studies have suggested lutein as a potential treatment with positive effects on macular pigment density. The objective of this study was to examine the effect of lutein supplementation on preservation of visual function in patients with retinitis pigmentosa (RP) METHODS: In a double-masked randomized placebo-controlled phase I/II clinical trial with a cross-over design, 34 adult patients with RP were randomized to two groups. One group, consisted of 16 participants, received lutein supplementation (10 mg/d for 12 wks followed by 30 mg/d) for the first 24 weeks and then placebo for the following 24 weeks, while the other group included 18 participants for whom placebo (24 weeks) was administered prior to lutein. Visual acuity, contrast sensitivity, and central visual field were measured at different illumination levels at baseline and every week using a PC-based test at home. For visual acuity (VA) at normal illumination level, treatment with lutein reduced logMAR, i.e. improved VA, but this effect was not statistically significant. The changes in normal (100%), low (4%), and very low (0.1%) illumination log CS were not statistically significant (p-values: 0.34, 0.23, and 0.32, respectively). Lutein had a statistically significant effect on visual field (p-value: 0.038) and this effect increased in the model assuming a 6-week delay in effect of lutein. Comparing the development of vision measures against the natural loss expected to occur over the course of 48 weeks, most measures showed reduced decline, and these reductions were significant for normal illumination VA and CS. These results suggest that lutein supplementation improves visual field and also might improve visual acuity slightly, although these results should be interpreted cautiously. As a combined phase I and II clinical trial, this study demonstrated the efficacy and safety of lutein supplementation.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 3%
Australia 1 1%
Unknown 73 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 17%
Student > Bachelor 11 14%
Student > Ph. D. Student 10 13%
Student > Master 10 13%
Professor > Associate Professor 5 7%
Other 9 12%
Unknown 18 24%
Readers by discipline Count As %
Agricultural and Biological Sciences 14 18%
Medicine and Dentistry 13 17%
Nursing and Health Professions 4 5%
Biochemistry, Genetics and Molecular Biology 4 5%
Computer Science 3 4%
Other 15 20%
Unknown 23 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 November 2021.
All research outputs
#18,541,268
of 22,963,381 outputs
Outputs from BMC Ophthalmology
#1,560
of 2,371 outputs
Outputs of similar age
#60,794
of 64,782 outputs
Outputs of similar age from BMC Ophthalmology
#4
of 4 outputs
Altmetric has tracked 22,963,381 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,371 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 64,782 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 3rd percentile – i.e., 3% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.